[1]
|
Short, M.W., Burgers, K.G. and Fry, V.T. (2017) Esophageal Cancer. American Family Physician, 95, 22-28.
|
[2]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[3]
|
Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[4]
|
Lee, S. and Co-hen, D.J. (2019) Pharmacotherapy for Metastatic Esophageal Cancer: Where Do We Need to Improve? Expert Opinion on Pharmacotherapy, 20, 357-366. https://doi.org/10.1080/14656566.2018.1551881
|
[5]
|
Hirano, H. and Kato, K. (2019) Systemic Treatment of Advanced Esophageal Squamous Cell Carcinoma: Chemotherapy, Molecular-Targeting Therapy and Immunotherapy. Japanese Journal of Clinical Oncology, 49, 412-420.
https://doi.org/10.1093/jjco/hyz034
|
[6]
|
Schizas, D., Charalampakis, N., Kole, C., et al. (2020) Immunotherapy for Esophageal Cancer: A 2019 Update. Immunotherapy, 12, 203-218. https://doi.org/10.2217/imt-2019-0153
|
[7]
|
Wilke, H., Muro, K., Van Cutsem, E., et al. (2014) Ramucirumab Plus Paclitaxel versus Placebo Plus Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial. The Lancet Oncology, 15, 1224-1235.
https://doi.org/10.1016/S1470-2045(14)70420-6
|
[8]
|
Kojima, T. and Doi, T. (2017) Immunotherapy for Esopha-geal Squamous Cell Carcinoma. Current Oncology Reports, 19, Article No. 33. https://doi.org/10.1007/s11912-017-0590-9
|
[9]
|
Chen, Y., Wu, X., Hao, D., et al. (2019) Neoadjuvant Nimotuzumab Plus Chemoradiotherapy Compared to Neoadjuvant Chemoradiotherapy and Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma. Oncotarget, 10, 4069-4078. https://doi.org/10.18632/oncotarget.23861
|
[10]
|
Zhang, X., Jia, J., Lu, M., et al. (2019) Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-Up of a Phase II Study. Journal of Cancer, 10, 1409-1416.
https://doi.org/10.7150/jca.28659
|
[11]
|
Shankaran, V., Ikeda, H., Bruce, A.T., et al. (2001) IFNgamma and Lym-phocytes Prevent Primary Tumour Development and Shape Tumour Immunogenicity. Nature, 410, 1107-1111. https://doi.org/10.1038/35074122
|
[12]
|
Dunn, G.P., Old, L.J. and Schreiber, R.D. (2004) The Three Es of Cancer Immunoediting. Annual Review of Immunology, 22, 329-360. https://doi.org/10.1146/annurev.immunol.22.012703.104803
|
[13]
|
Zhang, L., Conejo-Garcia, J.R., Katsaros, D., et al. (2003) Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. The New England Journal of Medicine, 348, 203-213. https://doi.org/10.1056/NEJMoa020177
|
[14]
|
Blattman, J.N. and Greenberg, P.D. (2004) Cancer Immunotherapy: A Treatment for the Masses. Science, 305, 200-205.
https://doi.org/10.1126/science.1100369
|
[15]
|
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Can-cer Immunotherapy. Nature Reviews Cancer, 12, 252-264. https://doi.org/10.1038/nrc3239
|
[16]
|
Tanaka, T., Nakamura, J. and Noshiro, H. (2017) Promising Immunotherapies for Esophageal Cancer. Expert Opinion on Biological Therapy, 17, 723-733. https://doi.org/10.1080/14712598.2017.1315404
|
[17]
|
Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Current Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
|
[18]
|
Topalian, S.L., Taube, J.M. and Pardoll, D.M. (2020) Neoadjuvant Checkpoint Blockade for Cancer Im-munotherapy. Science, 367, eaax0182. https://doi.org/10.1126/science.aax0182
|
[19]
|
Ott, P.A., Elez, E., Hiret, S., et al. (2017) Pembrolizumab in Patients with Extensive-Stage Small-Cell Lung Cancer: Results from the Phase Ib KEYNOTE-028 Study. Journal of Clinical Oncology, 35, 3823-3829.
https://doi.org/10.1200/JCO.2017.72.5069
|
[20]
|
Shah, M.A., Kojima, T., Hochhauser, D., et al. (2019) Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients with Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. JAMA Oncology, 5, 546-550. https://doi.org/10.1001/jamaoncol.2018.5441
|
[21]
|
Del Pozo Martín, Y. (2019) 2019 ASCO Annual Meeting. The Lancet Oncology, 20, 909-910.
https://doi.org/10.1016/S1470-2045(19)30384-5
|
[22]
|
Kato, K., Cho, B.C., Takahashi, M., et al. (2019) Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant To Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet On-cology, 20, 1506-1517.
https://doi.org/10.1016/S1470-2045(19)30626-6
|